Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors

• Published in: Anticancer research 2021-08, Vol.41 (8), p.3955-3968
• Main Authors: JIMENEZ ROMERO, MIGUEL E., GALLEGO, MARIA CAMACHO, NAVARRO SERRATO, JOSE C., SANCHEZ HURTADO, MIGUEL A., SANTOTORIBIO, JOSE D.
• Format: Article
• Language: English
• Subjects: Acetic acid; Alkaline phosphatase; Castration; Chemotherapy; Combined treatment; Diagnosis; Markers; Medical prognosis; Metastases; Pain; Patients; Prednisone; Prostate cancer; Risk groups; Serum levels; Survival; Tumors
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.15192

Background/Aim: The aim of the study was to evaluate the combined treatment with abiraterone acetate and prednisone (AA+P) in patients with castration-resistant prostate cancer (mCPRC), and to identify the survival prognostic factors. Patients and Methods: Patients diagnosed with mCPRC not previously treated with chemotherapy and administered with AA+P were classified into two groups: those with lower and higher survival rates (at 30 months vs. 60 months). Results: A total of 53 patients were studied at the time of mCRPC diagnosis. Patients with the highest survival rate had suffered prostate cancer for >45 months. At the time of initial prostate cancer diagnosis, they belonged to the risk groups 1-4, had pain intensity measured according to the brief pain inventory (BPI) scale of 0-2, were treated with AA+P>16 months, and had the following tumour marker serum levels: LDH baseline ≤163 U/l, alkaline phosphatase at 6 months ≤56 U/l and PSA at 6 months ≤0.95 ng/ml. Conclusion: Good response to treatment with AA+P for patients with mCRPC was demonstrated. Factors that contributed to the higher prognostic accuracy were time suffering from prostate cancer, the intensity of the pain measured by the BPI scale, the duration of AA+P treatment, and tumour marker levels.